Phase 3
Completed N=147
Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.
video-assisted thoracoscopic surgery · Pain, Postoperative · Pain, Acute
Source: ClinicalTrials.gov NCT03151434 ↗
Enrolled (actual)
147
Serious AEs
0.0%
Results posted
Jan 2021
Primary outcomePrimary: The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours — 4.0; 4.5; 3.0 units on a scale
◆ Published Evidence
Established
57citations · ~10 / year
Randomized Prospective Study Evaluating Single-Injection Paravertebral Block, Paravertebral Catheter, and Thoracic Epidural Catheter for Postoperative Regional Analgesia After Video-Assisted Thoracoscopic Surgery.
Summary
The purpose of this study is to compare three different pain control methods on subjects who are scheduled to undergo VATS (video-assisted thoracoscopic surgery) procedures. The study will compare their pain scores, narcotic needs, patient satisfaction scores, and narcotic side effects.
Linked Publications
-
Randomized Prospective Study Evaluating Single-Injection Paravertebral Block, Paravertebral Catheter, and Thoracic Epidural Catheter for Postoperative Regional Analgesia After Video-Assisted Thoracoscopic Surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Primary Endpoint of This Study Will be VAS Pain Score at 24 Hours |
4.0; 4.5; 3.0 | — |
| PRIMARY The Primary Endpoint of This Study Will be VAS Pain Score at 48 Hours |
3.0; 4.0; 2.0 | — |
| SECONDARY Secondary Endpoint Includes Total Intravenous Opioid Consumption at 72 Hours |
57; 35; 21.3 | — |
Eligibility Criteria
Inclusion Criteria
- Pt undergoing VATS procedure at Indiana University Hospital
- ASA 1,2,3 or 4
- Age 18 or older, male or female
- Desires Regional anesthesia for postoperative pain control
Exclusion Criteria
- Any contraindication for Thoracic Epidural or Paravertebral block
- History of substance abuse in the past 6 months
- Patient staying intubated after surgery
- Known allergy or other contraindications to the study medications , which include dilaudid, bupivacaine, ropivacaine
Data sourced from ClinicalTrials.gov (NCT03151434) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.